Theravance Biopharma, Inc.

Form 4

Ordinary

Shares

November 24, 2015

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL				
			AND EX , D.C. 20	COMMISSION	OMB Number:	3235-028					
Check th if no long	705								Expires:	January 31	
subject to Section 16. Form 4 or				SECUE	RITIES				Estimated average burden hours per response		
obligatio may cont See Instru 1(b).	ns Section	17(a) of the	Public U	tility Hol		npan	y Act of	e Act of 1934, § 1935 or Section § 0	1		
(Print or Type I	Responses)										
			Symbol	2. Issuer Name and Ticker or Trading ymbol				5. Relationship of Reporting Person(s) to Issuer			
			Therava	ance Biop	pharma, I	nc. [7	ГВРН]	(Checl	k all applicable)	
				of Earliest Transaction Day/Year) 2015				Director 10% Owner Other (specify below)			
US, INC., 9	UIGAIEWA	I BLVD.						Sr. VP, Te	echnical Operat	ions	
				endment, Date Original nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
SOUTH SA FRANCISC	N CO, CA 94080							Form filed by M Person	lore than One Re	porting	
(City)	(State)	(Zip)	Tabl	le I - Non-l	Derivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	y Owned	
1.Title of Security (Instr. 3)	2. Transaction I (Month/Day/Ye	ear) Execution any		Code (Instr. 8)	4. Securi on(A) or D (Instr. 3,	(A) or	d of (D) 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Ordinary Shares	11/20/2015			F Code V	Amount 1,037	(D)	Price \$ 17.17	170,384 (1)	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

 $9,000 \frac{(2)}{}$

I

By spouse

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Title	and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onNumber	Expiration Date		Amount	t of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Underly	ing	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securitie	es	(Instr. 5)	Bene
	Derivative				Securities			(Instr. 3	and 4)		Own
	Security				Acquired						Follo
	•				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
								Λ.	mount		
									mount		
						Date	Expiration Date	or Title Number of			
						Exercisable					
				C + V	(A) (D)						
				Code V	(A) (D)			S	hares		

Reporting Owners

Relationships Reporting Owner Name / Address Officer Other Director 10% Owner

LEE JUNNING C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080

Sr. VP, Technical Operations

Signatures

Junning Lee 11/24/2015 **Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes 1,701 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 13, 2015.
- By Spouse as holder of self directed retirement account. Reporting person disclaims beneficial ownership of these securities in excess of **(2)** his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2